Literature DB >> 11571477

Outcome after transplantation of young patients with systemic lupus erythematosus: a report of the North American pediatric renal transplant cooperative study.

S M Bartosh1, R N Fine, E K Sullivan.   

Abstract

BACKGROUND: The risk of progressing to end-stage renal disease in children with lupus glomerulonephritis is 18% to 50%. Published reports of transplantation secondary to end-stage renal failure in adult patients with systemic lupus erythematosus (SLE) demonstrate equivalent patient and graft survival. The purpose of this analysis is to compare patient and graft outcomes of pediatric SLE renal transplant recipients with an age-, race-, and gender-matched control group.
METHODS: A retrospective analysis of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) database identified 100 renal transplants performed in 94 young SLE patients. A control group of 470 children having received 501 renal transplants was identified.
RESULTS: The SLE cohort was primarily female (82%), non-Caucasian (61%), adolescents and differed from the control group in being less likely to be preemptively transplanted, in receiving longer pretransplant dialysis, and in being likely to have received more than five pretransplant transfusions. After transplantation, there were no differences seen in patient survival at 3 years (89% vs. 95%, SLE vs. control) or in overall graft failure rates (31% vs. 29%, SLE vs. control). There was a trend toward poorer graft survival in non-white SLE patients receiving living donor grafts compared with white SLE patients. An increased graft failure rate was seen among those SLE cadaveric transplant recipients receiving peritoneal dialysis before transplant compared with controls and compared with SLE patients receiving hemodialysis. No differences were seen in rates of acute tubular necrosis or overall acute rejection incidence, although there was a significant increase in the percentage of living donor SLE patients who experienced greater than four rejection episodes. There were nonsignificant trends toward increased graft loss due to patient death with a functioning graft as well as increased mortality secondary to infection in the SLE patients.
CONCLUSIONS: The results of renal transplantation in young SLE patients are comparable to those seen in an age-, race- and gender-matched control group. The similar patient and graft survival is seen despite the SLE patients having an underlying disease with multiorgan involvement and despite receiving immunosuppression for potentially prolonged periods before transplantation. No outcome differences were seen except for an unexplained increase in the incidence of recurrent rejections (> or =4) in the living donor SLE patients as well as increased graft failure rate in those patients receiving cadaveric renal transplants after a period of peritoneal dialysis. The nonsignificant trends toward increased graft failures in non-white SLE patients receiving living donor grafts, increased graft loss secondary to death with a functioning graft, as well as the increased mortality due to infection deserve recognition and further study.

Entities:  

Mesh:

Year:  2001        PMID: 11571477     DOI: 10.1097/00007890-200109150-00047

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  16 in total

Review 1.  Ethnic disparities in patients with systemic lupus erythematosus.

Authors:  América G Uribe; Graciela S Alarcón
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

2.  Increased risk of death in pediatric and adult patients with ESRD secondary to lupus.

Authors:  Sangeeta Sule; Barbara Fivush; Alicia Neu; Susan Furth
Journal:  Pediatr Nephrol       Date:  2010-10-03       Impact factor: 3.714

3.  End-stage renal disease as the presenting manifestation of renal systemic lupus erythematosus.

Authors:  Lavjay Butani
Journal:  Pediatr Nephrol       Date:  2006-09-15       Impact factor: 3.714

4.  Report of an NIH task force on research priorities in chronic kidney disease in children.

Authors:  Russell W Chesney; Eileen Brewer; Marva Moxey-Mims; Sandra Watkins; Susan L Furth; William E Harmon; Richard N Fine; Ronald J Portman; Bradley A Warady; Isidro B Salusky; Craig B Langman; Debbie Gipson; Peter Scheidt; Harold Feldman; Frederick J Kaskel; Norman J Siegel
Journal:  Pediatr Nephrol       Date:  2005-10-27       Impact factor: 3.714

5.  Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children.

Authors:  Shuichiro Fujinaga; Kazunari Kaneko; Yoshiyuki Ohtomo; Hitohiko Murakami; Masaru Takada; Shunji Akashi; Mayako Hira; Yuichiro Yamashiro
Journal:  Pediatr Nephrol       Date:  2005-07-15       Impact factor: 3.714

Review 6.  Improving outcomes in patients with lupus and end-stage renal disease.

Authors:  Antonio Inda-Filho; Joel Neugarten; Chaim Putterman; Anna Broder
Journal:  Semin Dial       Date:  2013-09-04       Impact factor: 3.455

Review 7.  Kidney transplantation in patients with systemic lupus erythematosus.

Authors:  Sophia Lionaki; Chrysanthi Skalioti; John N Boletis
Journal:  World J Transplant       Date:  2014-09-24

8.  End-stage renal disease due to lupus nephritis among children in the US, 1995-2006.

Authors:  Linda T Hiraki; Bing Lu; Steven R Alexander; Tamara Shaykevich; Graciela S Alarcón; Daniel H Solomon; Wolfgang C Winkelmayer; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2011-07

Review 9.  Advances in the care of children with lupus nephritis.

Authors:  Scott E Wenderfer; Natasha M Ruth; Hermine I Brunner
Journal:  Pediatr Res       Date:  2016-11-17       Impact factor: 3.756

10.  Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution.

Authors:  Paula I Burgos; Elizabeth L Perkins; Guillermo J Pons-Estel; Scott A Kendrick; Jigna M Liu; William T Kendrick; William J Cook; Bruce A Julian; Graciela S Alarcón; Clifton E Kew
Journal:  Arthritis Rheum       Date:  2009-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.